Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 1/20 | 1.00 |
| ▸ | PAOX | Q6QHF9 | 3/20 | 0.76 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | EPHX1 | P07099 | 6/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | CASP2 | P42575 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hexamethylenebisacetamide SCHEMBL61980 | 1.00 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL1846096 | 1.00 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL10937726 | 1.00 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL6516953 | 1.00 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL14740196 | 1.00 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL14739904 | 1.00 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL1900654 | 1.00 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL1847535 | 1.00 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL14740132 | 1.00 | KDM4E (1.00) | KDM4EMAPK1HIF1APAOXADRA1A | |
| SCHEMBL860791 | 0.97 | KDM4E (0.94) | KDM4EMAPK1HIF1APAOXADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9562183-B2 | Use of compounds with nitrogen-containing functional groups for thermal energy storage | ARKEMA FRANCE (FR) | 2017-02-07 | — | — | US | disclosed |
| US-20130056175-A1 | USE OF COMPOUNDS WITH NITROGEN-CONTAINING FUNCTIONAL GROUPS FOR THERMAL ENERGY STORAGE | ARKEMA FRANCE (FR) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130056175-A1 | USE OF COMPOUNDS WITH NITROGEN-CONTAINING FUNCTIONAL GROUPS FOR THERMAL ENERGY STORAGE | S100A4, NUCB2, C9 | KDM4E 3957/4885MAPK1 1828/4885HIF1A 2482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.